Posted inUncategorized

US biotech stocks up fourth-straight day on cancer treatment advancements

Gilead Sciences is among the top gainers in the S&P 500 Health Care, on plans to buy Kite Pharma, currently developing immunotherapy treatment to compete with CAR T, according to a report from Bloomberg. Following yesterday’s approval of CAR T treatment, Impax Labs, along with other companies developing gene-based treatments, such as Intellia, NantKwest and […]